Investments support Sequenta MRD test
SOUTH SAN FRANCISCO, Calif.—Sequenta Inc. has announced that Celgene Corp., along with other strategic investors, has made an equity investment in the company. The funding will support Sequenta’s incorporation of the ClonoSIGHT minimal residual disease (MRD) test into clinical trials of medicines being developed for various blood cancers as well as development of clinical diagnostics based on the company’s LymphoSIGHT platform.
“The ClonoSIGHT MRD test has been validated across multiple blood cancers, and is used as a clinical decision-making tool by physicians at major cancer centers throughout the United States,” said Tom Willis, CEO of Sequenta. “Celgene’s investment in Sequenta, along with the other strategic investors, will further support adoption of our powerful minimal residual disease detection and quantification technology as the emerging standard for response assessment and disease monitoring in clinical trials of medicines for blood cancers, as well as the development of new applications of our LymphoSIGHT platform.”